Inhibition of IL-6 trans-signaling in the brain increases sociability in the BTBR mouse model of autism

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 10, 2016, Pages 1918-1925

  Wei, Hongen ^a   Ma, Yuehong ^a   Liu, Jianrong ^a   Ding, Caiyun ^a   Jin, Guorong ^a   Wang, Yi ^a   Hu, Fengyun ^a   Yu, Li ^a  

^a SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Autism; BTBR; Glutamate release; IL 6; Sociability

Indexed keywords

GLUTAMIC ACID; INTERLEUKIN 6; PROTEIN INHIBITOR; SGP130FC PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTISM; BRAIN CORTEX; CONTINUOUS INFUSION; CONTROLLED STUDY; DENDRITIC SPINE; FEMALE; MALE; MOUSE; NEUROMODULATION; NONHUMAN; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; SOCIAL INTERACTION;

EID: 84994521900     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2016.07.013     Document Type: Article

References (48)

1. [1] Gottfried, C., Bambini, V., Francis, F., Riesgo, R., Savino, W., The impact of neuroimmune alterations in autism spectrum disorder. Front. Psychiatry, 6, 2015.
2. [2] Wei, H., Alberts, I., Li, X., Brain IL-6 and autism. Neuroscience 252 (2013), 320–325.
3. [3] Spooren, A., Kolmus, K., Laureys, G., Clinckers, R., De Keyser, J., Haegeman, G., Gerlo, S., Interleukin-6, a mental cytokine. Brain Res. Rev. 67 (2011), 157–183.
4. [4] Garay, P.A., McAllister, A.K., Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders. Front Synaptic Neurosci., 2, 2010, 136.
5. [5] Schaper, F., Rose-John, S., Interleukin-6: Biology, signaling and strategies of blockade. Cytokine Growth Factor Rev. 26 (2015), 475–487.
6. [6] Vargas, D.L., Nascimbene, C., Krishnan, C., Zimmerman, A.W., Pardo, C.A., Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann. Neurol. 57 (2005), 67–81.
7. [7] Li, X., Chauhan, A., Sheikh, A.M., Patil, S., Chauhan, V., Li, X.M., Ji, L., Brown, T., Malik, M., Elevated immune response in the brain of autistic patients. J. Neuroimmunol. 207 (2009), 111–116.
8. [8] Wei, H., Zou, H., Sheikh, A.M., Malik, M., Dobkin, C., Brown, W.T., Li, X., IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. J. Neuroinflammation, 8, 2011, 52.
9. [9] Wei, H., Chadman, K.K., McCloskey, D.P., Sheikh, A.M., Malik, M., Brown, W.T., Li, X., Brain IL-6 elevation causes neuronal circuitry imbalances and mediates autism-like behaviors. Biochim. Biophys. Acta 1822 (2012), 831–842.
10. [10] Wei, H., Mori, S., Hua, K., Li, X., Alteration of brain volume in IL-6 overexpressing mice related to autism. Int. J. Dev. Neurosci. 30 (2012), 554–559.
11. [11] Meyza, K.Z., Defensor, E.B., Jensen, A.L., Corley, M.J., Pearson, B.L., Pobbe, R.L., Bolivar, V.J., Blanchard, D.C., Blanchard, R.J., The BTBR T + tf/J mouse model for autism spectrum disorders-in search of biomarkers. Behav. Brain Res. 251 (2013), 25–34.
12. [12] Silverman, J.L., Tolu, S.S., Barkan, C.L., Crawley, J.N., Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 35 (2010), 976–989.
13. [13] McFarlane, H.G., Kusek, G.K., Yang, M., Phoenix, J.L., Bolivar, V.J., Crawley, J.N., Autism-like behavioral phenotypes in BTBR T + tf/J mice. Genes Brain Behav. 7 (2008), 152–163.
14. [14] Heo, Y., Zhang, Y., Gao, D., Miller, V.M., Lawrence, D.A., Aberrant immune responses in a mouse with behavioral disorders. PLoS One, 6, 2011, e20912.
15. [15] Yang, M., Clarke, A.M., Crawley, J.N., Postnatal lesion evidence against a primary role for the corpus callosum in mouse sociability. Eur. J. Neurosci. 29 (2009), 1663–1677.
16. [16] Wei, H., Malik, M., Sheikh, A.M., Merz, G., Ted Brown, W., Li, X., Abnormal cell properties and down-regulated FAK-Src complex signaling in B lymphoblasts of autistic subjects. Am. J. Pathol. 179 (2011), 66–74.
17. [17] Ippolito, D.M., Eroglu, C., Quantifying synapses: an immunocytochemistry-based assay to quantify synapse number. J. Vis. Exp., 45, 2010 (pii: 2270).
18. [18] Christopherson, K.S., Ullian, E.M., Stokes, C.C., Mullowney, C.E., Hell, J.W., Agah, A., Lawler, J., Mosher, D.F., Bornstein, P., Barres, B.A., Thrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis. Cell 120 (2005), 421–433.
19. [19] Jaworski, J., Kapitein, L.C., Gouveia, S.M., Dortland, B.R., Wulf, P.S., Grigoriev, I., Camera, P., Spangler, S.A., Di Stefano, P., Demmers, J., Krugers, H., Defilippi, P., Akhmanova, A., Hoogenraad, C.C., Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity. Neuron 61 (2009), 85–100.
20. [20] Shen, H.W., Toda, S., Moussawi, K., Bouknight, A., Zahm, D.S., Kalivas, P.W., Altered dendritic spine plasticity in cocaine-withdrawn rats. J. Neurosci. 29 (2009), 2876–2884.
21. [21] Peca, J., Feliciano, C., Ting, J.T., Wang, W., Wells, M.F., Venkatraman, T.N., Lascola, C.D., Fu, Z., Feng, G., Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472 (2011), 437–442.
22. [22] Schwartz-Bloom, R.D., Engblom, A.C., Akerman, K.E., Inglefield, J.R., Measurement of chloride movement in neuronal preparations. Curr. Protoc. Neurosci., 2001 (Chapter 7). (Unit7 10).
23. [23] Villasana, L.E., Klann, E., Tejada-Simon, M.V., Rapid isolation of synaptoneurosomes and postsynaptic densities from adult mouse hippocampus. J. Neurosci. Methods 158 (2006), 30–36.
24. [24] Nicholls, D.G., Sihra, T.S., Sanchez-Prieto, J., Calcium-dependent and -independent release of glutamate from synaptosomes monitored by continuous fluorometry. J. Neurochem. 49 (1987), 50–57.
25. [25] Sim, A.T., Herd, L., Proctor, D.T., Baldwin, M.L., Meunier, F.A., Rostas, J.A., High throughput analysis of endogenous glutamate release using a fluorescence plate reader. J. Neurosci. Methods 153 (2006), 43–47.
26. [26] Volk, L., Chiu, S.L., Sharma, K., Huganir, R.L., Glutamate synapses in human cognitive disorders. Annu. Rev. Neurosci. 38 (2015), 127–149.
27. [27] Sheng, M., Kim, E., The postsynaptic organization of synapses. Cold Spring Harb. Perspect. Biol., 3, 2011.
28. [28] Hollingsworth, E.B., McNeal, E.T., Burton, J.L., Williams, R.J., Daly, J.W., Creveling, C.R., Biochemical characterization of a filtered synaptoneurosome preparation from guinea pig cerebral cortex: cyclic adenosine 3′:5′-monophosphate-generating systems, receptors, and enzymes. J. Neurosci. 5 (1985), 2240–2253.
29. [29] Silverman, J.L., Oliver, C.F., Karras, M.N., Gastrell, P.T., Crawley, J.N., AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology 64 (2013), 268–282.
30. [30] Chadman, K.K., Fluoxetine but not risperidone increases sociability in the BTBR mouse model of autism. Pharmacol. Biochem. Behav. 97 (2011), 586–594.
31. [31] Campbell, I.L., Erta, M., Lim, S.L., Frausto, R., May, U., Rose-John, S., Scheller, J., Hidalgo, J., Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J. Neurosci. 34 (2014), 2503–2513.
32. [32] Jones, S.A., Scheller, J., Rose-John, S., Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121 (2011), 3375–3383.
33. [33] Jostock, T., Mullberg, J., Ozbek, S., Atreya, R., Blinn, G., Voltz, N., Fischer, M., Neurath, M.F., Rose-John, S., Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268 (2001), 160–167.
34. [34] Burton, M.D., Rytych, J.L., Freund, G.G., Johnson, R.W., Central inhibition of interleukin-6 trans-signaling during peripheral infection reduced neuroinflammation and sickness in aged mice. Brain Behav. Immun. 30 (2013), 66–72.
35. [35] Burton, M.D., Sparkman, N.L., Johnson, R.W., Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from lipopolysaccharide-induced sickness behavior. J. Neuroinflammation, 8, 2011, 54.
36. [36] Rodriguez-Barrueco, R., Yu, J., Saucedo-Cuevas, L.P., Olivan, M., Llobet-Navas, D., Putcha, P., Castro, V., Murga-Penas, E.M., Collazo-Lorduy, A., Castillo-Martin, M., Alvarez, M., Cordon-Cardo, C., Kalinsky, K., Maurer, M., Califano, A., Silva, J.M., Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR −/HER2 + breast cancers. Genes Dev. 29 (2015), 1631–1648.
37. [37] Marotta, L.L., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S.R., Bloushtain-Qimron, N., Kim, J.J., Choudhury, S.A., Maruyama, R., Wu, Z., Gonen, M., Mulvey, L.A., Bessarabova, M.O., Huh, S.J., Silver, S.J., Kim, S.Y., Park, S.Y., Lee, H.E., Anderson, K.S., Richardson, A.L., Nikolskaya, T., Nikolsky, Y., Liu, X.S., Root, D.E., Hahn, W.C., Frank, D.A., Polyak, K., The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(−) stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121 (2011), 2723–2735.
38. [38] Malkova, N.V., Yu, C.Z., Hsiao, E.Y., Moore, M.J., Patterson, P.H., Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain Behav. Immun. 26 (2012), 607–616.
39. [39] Smith, S.E., Li, J., Garbett, K., Mirnics, K., Patterson, P.H., Maternal immune activation alters fetal brain development through interleukin-6. J. Neurosci. 27 (2007), 10695–10702.
40. [40] Parker-Athill, E., Luo, D., Bailey, A., Giunta, B., Tian, J., Shytle, R.D., Murphy, T., Legradi, G., Tan, J., Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism. J. Neuroimmunol. 217 (2009), 20–27.
41. [41] Maes, M., Anderson, G., Kubera, M., Berk, M., Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?. Expert Opin. Ther. Targets 18 (2014), 495–512.
42. [42] Atzori, M., Garcia-Oscos, F., Mendez, J.A., Role of IL-6 in the etiology of hyperexcitable neuropsychiatric conditions: experimental evidence and therapeutic implications. Future Med. Chem. 4 (2012), 2177–2192.
43. [43] Garcia-Oscos, F., Salgado, H., Hall, S., Thomas, F., Farmer, G.E., Bermeo, J., Galindo, L.C., Ramirez, R.D., D'Mello, S., Rose-John, S., Atzori, M., The stress-induced cytokine interleukin-6 decreases the inhibition/excitation ratio in the rat temporal cortex via trans-signaling. Biol. Psychiatry 71 (2012), 574–582.
44. [44] Wei, H., Ding, C., Jin, G., Yin, H., Liu, J., Hu, F., Abnormal glutamate release in aged BTBR mouse model of autism. Int. J. Clin. Exp. Pathol. 8 (2015), 10689–10697.
45. [45] Rojas, D.C., The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment. J. Neural Transm. 121 (2014), 891–905.
46. [46] D'Arcangelo, G., Tancredi, V., Onofri, F., D'Antuono, M., Giovedi, S., Benfenati, F., Interleukin-6 inhibits neurotransmitter release and the spread of excitation in the rat cerebral cortex. Eur. J. Neurosci. 12 (2000), 1241–1252.
47. [47] Garcia-Oscos, F., Pena, D., Housini, M., Cheng, D., Lopez, D., Borland, M.S., Salgado-Delgado, R., Salgado, H., D'Mello, S., Kilgard, M.P., Rose-John, S., Atzori, M., Vagal nerve stimulation blocks interleukin 6-dependent synaptic hyperexcitability induced by lipopolysaccharide-induced acute stress in the rodent prefrontal cortex. Brain Behav. Immun. 43 (2015), 149–158.
48. [48] Goyal, K., Koul, V., Singh, Y., Anand, A., Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances. Cent. Nerv. Syst. Agents Med. Chem. 14 (2014), 43–59.